Early recognition and targeted management of supraventricular arrhythmias improve quality of life, morbidity, and mortality in patients with pulmonary hypertension.
This comprehensive review highlights the mechanistic drivers and clinical implications of supraventricular arrhythmias in pulmonary hypertension, emphasizing the need for early recognition and targeted management.
Absolute Event Rate: 0% vs 0%
Pulmonary Hypertension (PH) is a chronic disease that causes significant structural deterioration in the right atrium and ventricle. In the past 1-2 decades, life expectancy in patients with PH has increased due to improved awareness, diagnosis and advancements in treatment. Increasingly, PH is recognized in older patients with comorbidities. With the changing demographics, supraventricular arrhythmias (SVAs), especially atrial fibrillation and flutter, are emerging as important outcomes in PH. Here, we comprehensively summarize findings from preclinical and clinical studies to define the mechanistic drivers and clinical implications of SVA. In sum, we propose early recognition and targeted management of SVA is important to improve quality of life, morbidity and mortality in patients with PH.
Kiris et al. (Thu,) reported a other. Early recognition and targeted management of supraventricular arrhythmias improve quality of life, morbidity, and mortality in patients with pulmonary hypertension.